Key Developments: Apricus Biosciences Inc (APRI.O)

APRI.O on Consolidated Issue listed on NASDAQ Capital Market

1.44USD
31 Jul 2015
Change (% chg)

$0.01 (+0.70%)
Prev Close
$1.43
Open
$1.45
Day's High
$1.47
Day's Low
$1.27
Volume
107,457
Avg. Vol
121,380
52-wk High
$2.75
52-wk Low
$0.92

Search Stocks

Latest Key Developments (Source: Significant Developments)

Apricus Biosciences Inc announces issuance of U.S. patent for RayVa
Tuesday, 27 Jan 2015 04:30pm EST 

Apricus Biosciences Inc:Says that Jan. 27, United States Patent and Trademark Office (USPTO) issued to Apricus, U.S. Patent No. 8,940,794, titled "METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE," with claims generally directed to methods for treating Raynaud's phenomenon, that is secondary to systemic sclerosis.Patent is expected to expire no earlier than twenty-year term in 2032.RayVa is proprietary name for Apricus' product candidate for treatment of Raynaud's phenomenon.  Full Article

Apricus Biosciences Inc announces resignation of CFO - Form 8-K
Monday, 15 Dec 2014 04:06pm EST 

Apricus Biosciences Inc:Says on Dec. 12, 2014, Steve Martin tendered his resignation as the senior vice president, chief financial officer and secretary, such resignation to be effective immediately.  Full Article

Apricus Biosciences Inc announces launch of Vytaros
Monday, 3 Nov 2014 06:00am EST 

Apricus Biosciences Inc:Says launch of Vytaros in Belgium by Sandoz Division of Novartis Group of companies.Says novel topical on-demand treatment for erectile dysfunction ("ED"), being marketed in Belgium as Vytaros, is also marketed in other European countries as Vitaros.Product is currently approved in ten countries in Europe, including major ED markets such as aforementioned and France, Italy and Spain.Says company expects additional launches by its partners in these approved countries into 2015.  Full Article

Apricus Biosciences, Inc expands development pipeline with in licensing of U.S. Rights for Fispemifene
Monday, 20 Oct 2014 02:00am EDT 

Apricus Biosciences, Inc:Says that it has licensed the U.S. development and commercialization rights for a novel selective estrogen receptor modulator (SERM), fispemifene, an investigational treatment for urological conditions in men, from Forendo Pharma, a private therapeutics company based in Finland.Says this license agreement combines Apricus' expertise in men's health with Forendo's established leadership in SERM drug discovery, to advance the development of fispemifene as an investigational treatment for urological conditions in men.  Full Article

Apricus Biosciences Inc enters into common stock purchase agreement with Aspire Capital
Tuesday, 12 Aug 2014 07:00am EDT 

Apricus Biosciences Inc:Entered into common stock purchase agreement with Aspire Capital Fund, LLC (Aspire Capital).Aspire Capital has purchased 1,159,824 shares of common stock for proceeds of $2.0 mln upon execution of the purchase agreement and has committed to purchase up to $20.0 mln of additional shares of common stock over next 24 months at prices based on the market price at the time of each sale.No warrants are associated with this agreement.Apricus will issue 255,161 shares of common stock to Aspire Capital as commitment fee in connection with the execution of the purchase agreement.Any sales of shares of common stock to Aspire Capital pursuant to purchase agreement have been or will be pursuant to prospectus supplement to Company's prospectus, dated Jan.11, 2012 filed as part of Company's effective shelf registration statement on Form S-3 (File No. 333-178832).  Full Article

Apricus Biosciences Inc announces multi-year partnership with Scleroderma Research Foundation
Friday, 8 Aug 2014 07:30am EDT 

Apricus Biosciences Inc:Says multi-year partnership agreement with Scleroderma Research Foundation (SRF).Says to support the foundation's activities and the further progress of SRF's groundbreaking research programs.As part of partnership, Apricus will co-sponsor an upcoming Scleroderma Research Roundtable Series and plans to participate in SRF's Annual Scientific Workshop and an SRF-sponsored event to take place at upcoming American College of Rheumatology (ACR) 2014 annual meeting.  Full Article

Apricus Biosciences Inc announces launch of its topical treatment for erectile dysfunction Vitaros in Sweden by Sandoz
Monday, 4 Aug 2014 08:02am EDT 

Apricus Biosciences Inc:Announced launch of Vitaros, Apricus' topical on-demand treatment for erectile dysfunction (ED), by the Sandoz Division of the Novartis Group of Companies (Sandoz), in Sweden.  Full Article

Apricus Biosciences receives FDA clearance to begin clinical trial of RayVa(TM) for secondary Raynaud's Phenomenon
Monday, 12 May 2014 04:05pm EDT 

Apricus Biosciences Inc:Says U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application allowing to initiate clinical testing of RayVa for treatment of Raynaud's phenomenon.Expects to commence a Phase 2a clinical trial and begin enrollment in the second half of 2014.  Full Article

Apricus Biosciences Inc announces national phase approval for Vitaros in Spain
Thursday, 24 Apr 2014 08:00am EDT 

Apricus Biosciences Inc:Spanish Agency for Medicines and Health Products has granted national phase approval to Vitaros, Apricus' novel topical on-demand treatment for erectile dysfunction.With approval in Spain, Company has now received total of ten national phase approvals for Vitaros.  Full Article

Apricus Biosciences Inc and Recordati sign exclusive license agreement to market topical erectile dysfunction cream
Monday, 10 Feb 2014 07:00am EST 

Apricus Biosciences Inc:Signs exclusive license agreement with Recordati S.p.A. to market Vitaros, its topical on-demand product for the treatment of erectile dysfunction (ED), in Spain, Russia, Turkey, Ireland and certain other European and African countries.Under the terms of the agreement, Apricus is eligible to receive up to about $3.8 million from Recordati in upfront and pre-commercialization milestone payments.Apricus is also eligible to receive up to about $47 million in sales milestone payments, plus double-digit tiered royalties based on Recordati's net sales of the product in the Territory.  Full Article

Search Stocks